← Back to Search
Megakaryocyte Potentiation Factor Cleaved From Mesothelin Precursor Is A Useful Tumor Marker In The Serum Of Patients With Mesothelioma
M. Onda, Satoshi Nagata, M. Ho, T. Bera, R. Hassan, R. Alexander, I. Pastan
Published 2006 · Medicine, Biology
Download PDFAnalyze on Scholarcy
Purpose: To establish monoclonal antibodies (mAb) against megakaryocyte potentiation factor (MPF) and detect MPF in the blood of patients with mesothelioma. Experimental Design: Mice were immunized with a purified recombinant human MPF-rabbit-Fc fusion protein and with MPF. Several hybridomas producing mAbs to MPF were established. A double-determinant (sandwich) ELISA was constructed using mAbs to two different epitopes and used to determine if MPF is present in the serum of patients with mesothelioma. Results: We established seven anti-MPF mAbs whose topographical epitopes were classified into three nonoverlapping groups. All the mAbs reacted with recombinant MPF protein by ELISA. One of the mAbs detected MPF and the mesothelin precursor protein containing MPF in cell lysates on Western blotting. A sandwich ELISA using mAbs to two different epitopes was constructed and used to measure the presence of MPF in the media of various mesothelin-expressing cancer cell lines and in human serum. The ELISA showed that MPF levels were elevated in 91% (51 of 56) of patients with mesothelioma compared with healthy controls. Furthermore, serum MPF fell to normal levels in two patients after surgery for their peritoneal mesothelioma. Conclusions: Using new mAbs to MPF, we showed that MPF is secreted by several mesothelioma cell lines and is frequently elevated in the blood of patients with mesothelioma. Measurement of MPF may be useful in following the response of mesothelioma to treatment.
This paper references
New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA
M. Onda (2005)
A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5.
N. Yamaguchi (1994)
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
Indications for pneumonectomy . Extrap - leural pneumonectomy
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).
P. Argani (2001)
Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay.
Satoshi Nagata (2004)
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
N. Scholler (1999)
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intra peritoneal chemotherapy
A L Feldman (2003)
American Association for Cancer clincancerres.aacrjournals.org Downloaded from
TP-3 Immunotoxins Improve Antitumor Activity in Mice with Osteosarcoma
M. Onda (2005)
Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model.
Takehiko Murayama (2006)
Glycosylphosphatidylinosi - tolanchored proteins : structure , function , and cleavage by phosphatidylinositolspecific phospholipase C
FJ Sharon (2002)
Mesothelin Is Not Required for Normal Mouse Development or Reproduction
T. Bera (2000)
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
A. Feldman (2003)
Localization of Mesothelin in Epithelial Ovarian Cancer
R. Hassan (2005)
Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients
A. M. Thomas (2004)
J. Espinosa Arranz (1994)
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion*
A. Rump (2004)
Glycosylphosphatidylinositol-anchored proteins: structure, function, and cleavage by phosphatidylinositol-specific phospholipase C.
F. Sharom (2002)
Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients
M. Ho (2005)
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
DNA immunization followed by a single boost with cells: a protein-free immunization protocol for production of monoclonal antibodies against the native form of membrane proteins.
Satoshi Nagata (2003)
Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
M. Onda (2001)
Mesothelin: a new target for immunotherapy.
R. Hassan (2004)
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.
R. Hassan (2005)
Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA (*)
T. Kojima (1995)
Glycosylphosphatidylinosi - tol - anchored proteins : structure , function , and cleavage by phosphatidylinositol - specific phospholipase C
FJ Sharon (2002)
How GPI-anchored proteins turnover: or where do they go after arrival at the plasma membrane.
P. Censullo (1994)
Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium
K. Chang (1992)
Indications for pneumonectomy. Extrapleural pneumonectomy.
V. Rusch (1999)
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
R. Hassan (2006)
Changing trends in US mesothelioma incidence
H. Weill (2004)
Indications for pneumonectomy
Uglov Fg (1948)
Megakaryocyte Potentiation Factor as aTumor Marker www
Malignant mesothelioma in Australia, 1945-2000.
J. Leigh (2002)
Immunohistochemical diagnosis of mesothelioma
J. Legier (1994)
Malignant mesothelioma in Australia
A. Musk (2006)
Application of Mesothelin Immunostaining in Tumor Diagnosis
N. Ordóñez (2003)
This paper is referenced by
Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma.
L. Cao (2018)
Screening Issues in Exposed Subjects and Early Diagnosis
M. Mencoboni (2019)
Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.
K. Inami (2008)
Exploration of Biomarkers for Asbestos Exposure and Occurrence of Malignant Mesothelioma Based on the Immunological Effects of Asbestos
Hidenori Matsuzaki (2013)
PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA
Tommaso Claudio Mineo and Vincenzo Ambrogi (2016)
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice
J. Zhang (2014)
Effectiveness of serum megakaryocyte potentiating factor in evaluating the effects of chrysotile and its heated products on respiratory organs.
A. Takata (2011)
MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.
T. Segawa (2008)
Long-Term Response of Rats to Single Intratracheal Exposure of Libby Amphibole or Amosite
J. M. Cyphert (2012)
An Update on Biomarkers and Treatment
Mandira Ray (2015)
Diagnostic biomarker of asbestos‐related mesothelioma: Example of translational research
Hino Okio (2007)
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
Mesothelioma: Update on Diagnostic Strategies
Carmen M. Rosario (2012)
RAPID CONVERSION OF CHRONIC MYELOID LEUKEMIA TO CHRONIC MYELOMONOCYTIC LEUKEMIA IN A PATIENT ON IMATINIB THERAPY
J. Khorashad (2016)
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats
B. K. Sathyanarayana (2008)
Mésothéliome pleural : conséquences de la stadification sur la stratégie thérapeutique
L. Greillier (2007)
Molecular biomarkers in malignant mesothelioma: state of the art
S. Kao (2011)
- 1-Comparisons and combinations of the five tumor markers for mesothelioma : NERC / mesothelin , osteopontin , hyaluronic acid , CA 125 , and CYFRA 21-1
K. Shiomi (2011)
Malignant pleural mesothelioma : novel biomarkers and related pathways
Filip Mundt (2013)
Blood Tests for Asbestos-Related Mesothelioma
M. Maeda (2006)
Establishment of the enzyme‐linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin
M. Nakaishi (2007)
Diagnostic tumor marker of asbestos-related mesothelioma
O. Hino (2008)
A Comparison of Diffe rent Treatments for Mesothelioma
Samira Rezaei (2014)
Discovery of mesothelin and exploiting it as a target for immunotherapy.
I. Pastan (2014)
Clinical utility of diagnostic markers for malignant pleural mesothelioma.
B. Grigoriu (2009)
highlights several prognostic biomarkers for malignant mesothelioma.
Filip Mundt (2013)
A. Moore (2008)
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Ling Luo (2010)
Mesothelin Expression in the Leptomeninges and Meningiomas
M. Johnson (2008)See more